{"url_path":"/sec/wve/8-k/2026-05-18/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/1631574/0001193125-26-229076-index.html","accession_number":"0001193125-26-229076","cik":"0001631574","ticker":"WVE","issuer_name":"Wave Life Sciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1631574/0001193125-26-229076-index.html","primary_entity_key":"0001631574","primary_entity_name":"Wave Life Sciences Ltd."},"word_count":216,"has_tables":true,"body_markdown":"Item 7.01\n\nRegulation FD Disclosure.\n\nOn May 18, 2026, Wave Life Sciences Ltd. (the “Company” or “Wave”) issued a press release announcing a positive update from the ongoing RestorAATion-2 trial of WVE-006, its investigational, GalNAc-conjugated, subcutaneously delivered RNA editing oligonucleotide (AIMer) for alpha-1 antitrypsin deficiency (AATD). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.\n\nThe press release also indicated that Wave management will host an investor conference call at 5:30 p.m. ET on May 18, 2026, to review the RestorAATion-2 program and updated clinical data. For purposes of the call, and in connection with the announcement described above, the Company plans to share an investor slide presentation during the investor conference call, which will be available on the “Investors” section of the Company’s website at https://ir.wavelifesciences.com/.\n\nThe information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing."}